Patents by Inventor Vincent Weynants
Vincent Weynants has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11723966Abstract: The present invention relates to immunogenic compositions, such as vaccines, comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis, for use in methods of boosting an immune response and methods of treatment using same. More particularly, the invention relates to use of such immunogenic compositions in methods of treating or preventing exacerbation of chronic obstructive pulmonary disease.Type: GrantFiled: August 13, 2018Date of Patent: August 15, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ashwani Kumar Arora, Vincent Weynants
-
Publication number: 20220023409Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.Type: ApplicationFiled: October 12, 2021Publication date: January 27, 2022Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Catherine COHET, Jeanne-Marie Josephine DEVASTER, David MAYHEW, Bruce MILLER, Ruth TAL-SINGER, Vincent WEYNANTS, Thomas WILKINSON
-
Patent number: 11167022Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.Type: GrantFiled: March 29, 2018Date of Patent: November 9, 2021Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Catherine Cohet, Jeanne-Marie Josephine Devaster, David Mayhew, Bruce Miller, Ruth Tal-Singer, Vincent Weynants, Thomas Wilkinson
-
Publication number: 20200405841Abstract: The present invention relates to the field of immunogenic compositions and vaccines and the use of such compositions in medicine. More particularly, it relates to immunogenic fragments of UspA2 comprising an epitope and immunogenic compositions and vaccines comprising said fragments, for use in preventing or treating an infection, disease or condition caused by heterologous strain(s) of Moraxella catarrhalis. The invention further relates to immunogenic compositions and vaccines comprising an immunogenic fragment wherein said fragment comprises an epitope with cross-bactericidal activity.Type: ApplicationFiled: March 6, 2019Publication date: December 31, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nathalie Isabelle Devos, Vincent DEWAR, Philippe Vincent HERMAND, Silvia ROSSI PACCANI, Vincent WEYNANTS
-
Publication number: 20200197504Abstract: The present invention relates to immunogenic compositions, such as vaccines, comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis, for use in methods of boosting an immune response and methods of treatment using same. More particularly, the invention relates to use of such immunogenic compositions in methods of treating or preventing exacerbation of chronic obstructive pulmonary disease.Type: ApplicationFiled: August 13, 2018Publication date: June 25, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ashwani Kumar ARORA, Vincent WEYNANTS
-
Publication number: 20200046823Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.Type: ApplicationFiled: March 29, 2018Publication date: February 13, 2020Inventors: Catherine COHET, Jeanne-Marie Josephine DEVASTER, David MAYHEW, Bruce MILLER, Ruth TAL-SINGER, Vincent WEYNANTS, Thomas WILKINSON
-
Publication number: 20190008943Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.Type: ApplicationFiled: June 18, 2018Publication date: January 10, 2019Inventors: Jan POOLMAN, Nathalie Isabelle DEVOS, Michiel STORK, Johannes Petrus Maria TOMMASSEN, Vincent WEYNANTS
-
Publication number: 20170209562Abstract: The present disclosure relates to the field of Neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor H binding protein (fHbp) antigen. The present inventors have recognised that fHbp is poorly expressed in neisserial strains of ST269 clonal complex (a subset of strains which seems to be growing in terms of numbers of reported cases of disease attributed to it), and vaccines comprising fHbp may be made more effective against said strains by formulating the vaccine with a further antigen that can elicit protection against these strains.Type: ApplicationFiled: December 6, 2016Publication date: July 27, 2017Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Jan POOLMAN, Nathalie Isabelle DEVOS, Cindy CASTADO, Vincent WEYNANTS
-
Publication number: 20170080075Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.Type: ApplicationFiled: April 28, 2016Publication date: March 23, 2017Inventors: Jan POOLMAN, Nathalie Isabelle DEVOS, Michiel STORK, Johannes Petrus Maria TOMMASSEN, Vincent WEYNANTS
-
Patent number: 9567377Abstract: Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.Type: GrantFiled: March 10, 2011Date of Patent: February 14, 2017Assignee: GlaxoSmithKline Biologicals SAInventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
-
Publication number: 20160243211Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bactericidal antibodies are generated against said antigen. It has been found for the first time that this antigen's expression is zinc regulated and therefore methods are provided to upregulated expression through removal of the zinc repression mechanism of the cell or promoter, or through removal of zinc from the culture medium.Type: ApplicationFiled: January 7, 2016Publication date: August 25, 2016Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
-
Patent number: 9365624Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.Type: GrantFiled: March 11, 2011Date of Patent: June 14, 2016Assignees: GlaxoSmithKline Biologicals, S.A., Utrecht UniversityInventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants
-
Publication number: 20160082097Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: September 3, 2015Publication date: March 24, 2016Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 9259461Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.Type: GrantFiled: March 6, 2009Date of Patent: February 16, 2016Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
-
Patent number: 9023606Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.Type: GrantFiled: March 14, 2011Date of Patent: May 5, 2015Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
-
Patent number: 8679770Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.Type: GrantFiled: September 5, 2005Date of Patent: March 25, 2014Assignee: Glaxo Smith Kline Biologicals S.A.Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
-
Publication number: 20130045231Abstract: Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.Type: ApplicationFiled: March 10, 2011Publication date: February 21, 2013Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
-
Publication number: 20130011429Abstract: Immunogenic compositions and methods of their use, as well as processes for their production are provided herein.Type: ApplicationFiled: March 10, 2011Publication date: January 10, 2013Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
-
Publication number: 20130004530Abstract: Neisserial immunogenic compositions and vaccines, their manufacture and methods for the use of such compositions in medicine are provided herein.Type: ApplicationFiled: March 10, 2011Publication date: January 3, 2013Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
-
Publication number: 20130004510Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.Type: ApplicationFiled: March 11, 2011Publication date: January 3, 2013Inventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants